Absolutely not unless you are fighting serious obesity. In contrast, I can imagine low dose intermittent mTORC1 inhibition as generally advantageous over a much

Absolutely not unless you are fighting serious obesity. In contrast, I can imagine low dose intermittent mTORC1 inhibition as generally advantageous over a much wider population of individuals 50 years and older.